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Abstract
Introduction: We assessed whether modest systemic cooling started within 6 hours of symptom onset improves
functional outcome at three months in awake patients with acute ischaemic stroke.
Patients and methods: In this European randomised open-label clinical trial with blinded outcome assessment, adult
patients with acute ischaemic stroke were randomised to cooling to a target body temperature of 34.0–35.0C, started
within 6 h after stroke onset and maintained for 12 or 24 h , versus standard treatment. The primary outcome was the
score on the modified Rankin Scale at 91 days, as analysed with ordinal logistic regression.
Results: The trial was stopped after inclusion of 98 of the originally intended 1500 patients because of slow recruitment
and cessation of funding. Forty-nine patients were randomised to hypothermia versus 49 to standard treatment.
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Four patients were lost to follow-up. Of patients randomised to hypothermia, 15 (31%) achieved the predefined cooling
targets. The primary outcome did not differ between the groups (odds ratio for good outcome, 1.01; 95% confidence
interval, 0.48–2.13; p¼ 0.97). The number of patients with one or more serious adverse events did not differ between
groups (relative risk, 1.22; 95% confidence interval, 0.65–1.94; p¼ 0.52).
Discussion: In this trial, cooling to a target of 34.0–35.0C and maintaining this for 12 or 24 h was not feasible in the
majority of patients. The final sample was underpowered to detect clinically relevant differences in outcomes.
Conclusion: Before new trials are launched, the feasibility of cooling needs to be improved.
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Introduction
In selected patients with acute ischaemic stroke, intra-
venous thrombolysis and endovascular treatment
improve functional outcome.1–3 However, among
patients treated with thrombolysis within 3 hours of
stroke onset in clinical trials, 59% were dead or depen-
dent at the end of follow-up,1 and in trials of endovas-
cular treatment, 29–67% of the patients randomised to
the intervention arm were dead or dependent at three
months.3 In addition, only aminority of patients with
acute ischaemic stroke are eligible for revascularisation
therapies: the Action Plan for Stroke in Europe 2018–
2030 aims to achieve rates above 15% for intravenous
thrombolysis and above 5% for endovascular therapy
across Europe.4 For this reason, there is an urgent need
for additional treatment strategies that can be applied
in a broad range of patients.
Therapeutic hypothermia appears a promising can-
didate treatment. Systematic review and meta-analysis
of animal studies modelling ischaemic stroke have
shown convincingly that therapeutic hypothermia
reduces infarct size and improves neurological out-
comes. The benefit of hypothermia appears inversely
related to the temperature achieved, with a reduction
in infarct size of about one third with cooling to 35C
and by around 45% with cooling to 34C.5 Most phase
II clinical trials have reported that cooling awake
patients with ischaemic stroke to target temperatures
of 33–35C for 12–24 h is feasible and safe, despite an
increased risk of pneumonia in some studies.6–10 Both
safety and feasibility were confirmed in a recent phase
III clinical trial that was terminated prematurely after
inclusion of 120 of the intended 1600 patients.11 All
published trials were underpowered to detect any
effect of hypothermia on functional outcome.
In this randomised clinical trial, we aimed to assess
whether systemic cooling to a target body temperature
between 34.0C and 35.0C, started within 6 h of symp-
tom onset and maintained for 12 or 24 h, improves
functional outcome at three months in awake patients
with acute ischaemic stroke.
Methods
Study design
EuroHYP-1 was an investigator-initiated, internation-
al, multicentre, randomised, open-label, blinded
outcome (PROBE), parallel-group, clinical superiority
trial, registered at ClinicalTrials.gov as NCT01833312.
The trial was coordinated at the University Hospital
Erlangen and funded by the European Union’s (EU)
Seventh Framework Programme under grant agree-
ment n 278709. The final full study protocol is avail-
able as an online supplement to this paper; a summary
of the original study protocol and the final statistical
plan have been published.12,13 The trial was overseen
by a steering committee and by an independent data
and safety monitoring board. Coordination of other
trial activities such as training, monitoring, data man-
agement, and data analysis were divided over eight
institutions in seven European cities.
Participants could be enrolled by investigators from
36 hospital sites in nine countries: Belgium, Denmark,
Finland, France, Germany, Italy, Lithuania, Spain and
the UK. Investigators were certified by web-based
training modules on cooling procedures; training pro-
vided by manufacturers of cooling systems on their
devices; web-based certification on assessment of the
National Institutes of Health Stroke Scale (NIHSS)14
and modified Rankin Scale (mRS)15 and provision of
written instructions on trial-specific procedures.
Experience with therapeutic hypothermia in awake
patients with acute stroke was not a requirement.
Ethics approval was obtained in each country and
2 European Stroke Journal 0(0)
(where required) at each site before the start of the
study in that country or site. Patients or their represen-
tatives provided written informed consent according to
national and local regulations.
Patients
Patients were eligible if they had a diagnosis of acute
ischaemic stroke; an age of 18 years or older; a score on
the NIHSS of 6–18 inclusive; a score on the motor
response sub-scale of the Glasgow Coma Scale of 5
or 6; a pre-stroke score on the mRS  2; an estimated
body weight of 50–120 kg; a possibility to start thera-
peutic hypothermia within 6 h after onset of stroke; and
a possibility to start therapeutic hypothermia within
90min after start of alteplase administration in patients
receiving thrombolysis or a possibility to start thera-
peutic hypothermia within 90min after admission to
the trial site if not receiving thrombolysis. All patients
underwent CT or MRI brain imaging to exclude hae-
morrhage and other non-ischaemic causes of stroke;
the presence of early acute ischaemic signs (e.g. subtle
brain hypoattenuation, hyperattenuated artery), prior
infarcts, leukoaraiosis or brain atrophy were not exclu-
sion criteria as long as the acute changes were consis-
tent with the known time of symptom onset. An
overview of the reasons for exclusion from the trial is
available in the full study protocol.
In an attempt to enhance recruitment after inclusion
of the first 50 patients, and to accommodate the wide-
spread use of endovascular treatment, the upper limit
on the NIHSS was dropped and the time window to
start of treatment was increased to 150min after start
of alteplase administration in patients receiving throm-
bolysis at the trial site, to 150min after start of endo-
vascular treatment, if this was later, and to 150min
after admission to the trial site in patients not receiving
thrombolysis or in patients who had received throm-
bolysis at a different site, without a change in the max-
imum time to start of hypothermia of six hours after
symptom onset.
Treatment
Patients were allocated to hypothermia plus standard
care or to standard care alone. Randomisation was
performed through a web-based allocation service
and involved stratification by country andminimisa-
tion on: intention to give alteplase; intended method
of cooling (surface or endovascular); sex; stroke sever-
ity (dichotomised between NIHSS 12 and 13); age
(65 years or >65 years); visibility of a relevant ischae-
mic lesion on the first brain imaging (yes or no) and
time since symptom onset (4 h or 4–6 h).
In patients randomised to hypothermia, cooling was
started within 6 h after onset of symptoms and within
90min of start of thrombolysis (or within 90min of
hospital admission in patients who were not treated
with thrombolysis) with intravenous infusion of
20mL/kg refrigerated normal saline (4C) over 30–
60mins or a pre-specified surface cooling method,
depending on local practice and preference. As men-
tioned above, the maximum delay to start of treatment
after intravenous thrombolysis or study site admission
was increased to 150min after the first 50 patients.
Cooling was maintained at 34.0–35.0C for 24 h with
a surface or endovascular technique. The choice of the
cooling technique was at the discretion of the local
investigator, as long as protocol-specified devices
were used. Thereafter, patients were passively
rewarmed at a rate of 0.2 0.1C per hour until the
rectal or bladder temperature reached 36.0C, after
which the cooling device was disconnected. To increase
the feasibility of cooling and thereby to increase
recruitment, the duration of active cooling was reduced
from 24 to 12 hours after inclusion of the first
50 patients.
In patients randomised to hypothermia, shivering
and discomfort were prevented and treated with intra-
venous pethidine (max 500mg/24 h) and oral buspirone
(max 30mg/24 h). Patients who had difficulties swal-
lowing did not receive buspirone unless they had a
nasogastric tube. For the prevention of opioid-
induced nausea and vomiting, ondansetron or granise-
tron were recommended.
All patients were treated according to published
guidelines for the treatment of acute ischaemic stroke
and for secondary prevention.
Outcomes
The primary outcome was the score on the mRS at 91
days (14 days), as analysed with ordinal logistic
regression and expressed as a common odds ratio
(OR). Secondary outcome included death or dependen-
cy, defined as a score on the mRS> 2; death; score on
NIHSS; brain infarct size (on CT or MRI, volume,
centrally and blindly assessed); World Health
Organization Disability Assessment Schedule
(WHODAS) 2.0 score and EuroQoL-5D-5L score,16–18
all at 91 days, except for brain infarct size that was
assessed at 48 h. The primary safety variable was the
occurrence of serious adverse events (SAEs) until
day 91.
To allow blinded assessment of the primary outcome
and to enhance statistical power, the mRS at 91 days
was assessed by at least four independent adjudicators
based on a video recording of the mRS interview, with
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masking to treatment allocation, and coordinated from
the University of Glasgow.19
Sample size
We originally estimated that a total of 1474 patients
was required to detect an absolute reduction in the
risk of death or disability (mRS> 2) of 7% (corre-
sponding to an OR of 074) with 90% power at the
5% significance level (two sided) and allowing for 3%
loss to follow-up. This target sample size was rounded
to 1500 patients. When recruitment proved to be much
slower than expected, we aimed for 80% power, allow-
ing a reduction in the target sample size to 750 patients,
which were rounded to 800.
Statistical analysis
Primary and secondary efficacy outcomes were assessed
in the intention-to-treat population (all included
patients). The primary efficacy variable, the score on
the mRS at 91 days, was intended to be determined
with ordinal logistic regression. However, because the
proportional odds assumptions of the ordinal regres-
sion analyses were not fulfilled in any of the analyses of
the primary outcome, the two groups were also com-
pared using van Elteren’s test stratified by nationality,
as defined in the statistical analysis plan.13
For secondary and exploratory outcomes frequen-
cies and percentages per group as well as risk ratios
with 95% confidence intervals (CIs) were reported for
binary outcomes. We used logistic regression for binary
quantities, the general linear univariate model for con-
tinuous outcomes and the Poisson distribution or neg-
ative binomial distribution for rate outcomes. If the
assumptions of the Poisson or negative binomial
models were not fulfilled with reasonable approxima-
tion, a non-parametric method (van Elteren adjusted
by nationality of centre) would be used.
Predefined per-protocol analyses were performed in
all patients who had a body temperature 35.0C for
at least 6 hours during the active cooling period.
Results
Enrolment into the trial started in November 2013 and
was stopped in March 2018 after inclusion of 98
patients at 23 study sites because of slow recruitment
and the expiration of the funding period. Forty-nine
patients were randomly assigned to the hypothermia
group and 49 to the control group (Figure 1). At base-
line, the mean age of the patients was 70 years (range,
34–92) and the median score on the NIHSS 11 (inter-
quartile range (IQR), 7–17). Forty three (44%) were
female. Baseline characteristics were balanced between
the two groups (Table 1). One patient in the
hypothermia group and three in the control group
were lost to follow-up at 91 days.
Of the 49 patients randomised to hypothermia, 38
(77%) were cooled with surface cooling and 11 with an
endovascular technique. Twenty five patients (51%)
had a planned duration of active cooling of 24 h, and
24 (49%) of 12 h. Only 15 (31%) of the 49 patients
randomised to hypothermia achieved cooling to the
extent defined in the study protocol and had a body
temperature 35.0C for at least 6 h during the active
cooling period. On the first day after randomisation,
18 (37%) patients randomised to hypothermia and
12 (24%) controls were treated on an intensive care
unit or intermediate care unit/high dependency unit.
The other patients were treated on a stroke unit or
normal ward.
Body temperatures in the first 12 h after randomisa-
tion are shown in Figure 2.
Efficacy outcomes
In the intention-to-treat analysis, there was no differ-
ence between the groups in the scores on the mRS at 91
days (OR for good outcome, 1.01; 95% CI, 0.48–2.13;
p¼ 0.97; Figure 3). The same applied to the per-
protocol analysis, including 15 patients randomised to
hypothermia and 46 to standard treatment (OR, 1.07;
95% CI, 0.35–3.32; p¼ 0.91). There were also no differ-
ences in the risks of death or death or dependency at 91
days, the scores on the NIHSS or Visual Analogue
Scale (VAS) of the EQ-5D-5 L at 91 days, or infarct
volume at 48 h (Table 2). Per-protocol analyses yielded
essentially the same results as the intention-to-treat
analyses (data not shown).
Safety outcomes
Seventeen patients (38%) in the hypothermia group
and 14 controls (29%) had at least one serious adverse
event (relative risk, 1.22; 95% CI, 0.65–1.94; p¼ 0.52;
Table 3).
Figure 1. Flow of patients through the study.
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Discussion
The results of this trial provide no evidence that active
cooling to a target of 34.0–35.0C for 12–24 h started
within 6 h after onset of ischaemic stroke has an impact
on functional outcome at three months. However, with
98 patients included against an original target of 1500,
the trial was substantially underpowered to detect any
clinically relevant benefit or harm. In addition, only
one third of the patients randomised to hypothermia
reached the predefined cooling targets, which further
limits the interpretation of the findings.
We were disappointed by the small number of
patients included into the trial despite a project dura-
tion of six years, involvement of 36 trial sites and gen-
erous funding. We think this may be explained by
several factors. First, cooling awake patients with
ischaemic stroke is a complex intervention with which
most study sites had no experience. While centres rec-
ognised the importance of the scientific question, there
was some understandable caution in proceeding from
trial approval to recruitment. Regardless of training
and experience, inclusion of an eligible patient into
the trial required a major investment in time of study
staff during the full treatment period of 12 or 24 h, and
this was often not feasible. Next, the trial design,
regulatory and reporting requirements and the overall
degree of complexity had more in common with
industry-initiated trials than with academic-led so-
called ‘pragmatic’ trials. This further increased the
burden to local investigators. Earlier phase II trials of
hypothermia for patients with acute ischaemic stroke in
centres without previous experience with cooling
have suggested that much higher recruitment rates
are possible with more pragmatic trial designs.9,10
Third, we had chosen to distribute core trial activities
across a range of universities and enterprises across
Europe – on the view that such distribution was more
likely to lead to funding success – rather than a more
conventional centralised approach based in the institu-
tion of the study sponsor. In retrospect this was an
error, and impeded effective trial coordination. We
suggest that future EU-funded trials should have cen-
tral provision of core trial functions unless the appli-
cants can provide a compelling reason why this should
not be the case. Finally, initiation of study sites was
severely delayed due to very high and inconsistent
bureaucratic hurdles across Europe and the trial
being variously considered a device trial, a drug trial,
both, or neither in different jurisdictions, each operat-
ing under the same EU Clinical Trials Directive.
Previous small randomised trials had suggested that
cooling to targets ranging from 33C to 35C was
Figure 2. Body temperatures in the first 12 h after start of
treatment in the overall trial population.
Figure 3. Distribution of scores on the modified Rankin Scale at
91 days.
Table 1. Characteristics of patients at baseline.
Intervention Control
Characteristic n¼ 49 n¼ 49
Age–years mean (SD) 69.6 (11.8) 71.1 (12.0)
Male sex – no (%) 28 (57.1) 27 (55.1)
Body weight–kg mean (SD) 80 (14.2) 78.9 (13.4)
Height–m mean (SD) 170 (10.2) 169 (9.7)
NIHSS score–median (IQR) 11 (7–17) 11 (8–17)
Location of stroke in
left hemisphere – no (%)
17 (35) 19 (39)
Pre-stroke mRS score–
median (IQR)
0 (0–0) 0 (0–1)
Visible acute ischaemic
lesion on CT – no (%)
22 (44.9) 22 (44.9)
Systolic blood
pressure–mm Hg
154 (26) 153 (23)
Diastolic blood
pressure–mm Hg
84 (18) 85 (14)
Body temperature – C
mean (SD)
36.2 (0.49) 36.3 (0.48)
Treatment with i.v.
alteplase – no (%)
39 (79.6) 41 (83.7)
Time from stroke onset
to randomisation – min
203 (155–244) 220 (164–293)
mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke
Scale; IQR, interquartile range.
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feasible in the large majority of patients with acute
ischaemic stroke.6–11 However, these studies were per-
formed in a few centres, often with experience with
hypothermia, whereas our phase III trial included
patients in a total of 23 study sites of which just a
few had previous experience with cooling awake
patients with ischaemic stroke. Before being opened
for recruitment, the staff at each study site were not
only trained in the study protocol, but also in the tech-
nique of cooling. Unfortunately, our study showed that
it was not possible to achieve cooling targets in the
majority of non-sedated stroke patients, at the current
time with typical limited staffing and equipment resour-
ces that are available even in expert centres. One small
phase II trial in patients with ischaemic stroke has sug-
gested that surface cooling is feasible to 35.0C, but not
to 34.5C or 34.0C.10 Future trials of hypothermia in
awake patients with acute ischaemic stroke could there-
fore target a modest temperature reduction to 35.0C
within the usual care environment. Larger reductions in
temperature probably require not only more investiga-
tor experience, but also intensive nursing care on an
intensive care unit or high-dependency unit.
Shivering occurred in all our cooled patients and
has been reported as a common adverse effect in all
previous cooling trials involving awake patients with
acute ischaemic stroke, despite anti-shivering regimes.
Shivering could be the most important reason for not
reaching and maintaining target temperatures. In our
study, the dose of pethidine as the main anti-shivering
drug was limited to a maximum of 500mg during the
period of cooling, which is about half that adminis-
tered in previous trials targeting a body temperature
of 33C for 24 h8,11 and also substantially less than
that used in a trial testing surface cooling from 34.0
to 35.0C.10 The maximum pethidine dose of 500mg
in our trial was motivated by the maximum daily dose
in the drug’s summary of product characteristics
(SPC), to which other trials were apparently not
bound. The pethidine dose in our trial was however
higher than the dose of 23mg/kg used in a recent
surface cooling trial targeting a body temperature of
35C for 12 h.9 In that trial, pethidine was combined
with intravenous dexmedetomidine, which we did not
use because the SPC of dexmedetomidine reports
acute cerebrovascular conditions as a contraindication
to its use. We think that any new study on hypother-
mia in patients with acute ischaemic stroke should
only commence after the development and validation
of better methods to prevent shivering
and discomfort.
In our trial, cooling was associated with an increased
risk of pneumonia. This is in line with most previous
studies of hypothermia in patients with acute ischaemic
stroke, and with findings of a systematic review on
infections in patients treated with hypothermia for
any indication.20 In patients with acute stroke, the
occurrence of pneumonia has been associated with a
greater risk of a poor outcome.21 It is however uncer-
tain whether pneumonia can be prevented with prophy-
lactic treatment with an antibiotic, and whether this
might have an impact on outcome.22
Table 2. Secondary efficacy outcomes.
Intervention Control
Outcome n¼ 48 n¼ 46 RR (95% CI) p
Death – n (%) 5 (10.2) 4 (8.2) 1.25 (0.34–3.81) 0.73
Death or dependency – n (%) 24 (50.0) 28 (60.9) 0.82 (0.50–1.14) 0.29
NIHSS – median (IQR) 3 (1–11) 3 (1–8) – 0.39
EQ-5D-5L VAS – median (IQR) 70 (50–90) 67 (50–80) – 0.45
WHODAS 2.0 – median (IQR) 53.5 (5.8–86.5) 38.0 (12.0–74.0) – 0.11
Infarct volume/mL mean (95% CI) 37.5 (13.0–102.8) 34.3 (10.5–65.5) – 0.55
All outcomes are at 91 days, except for infarct volume, which is at 48 h.
RR: risk ratio; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; IQR: interquartile range; EQ-5D-5LVAS: Visual Analogue
Scale of the EuroQoL 5 dimensions 5 level questionnaire; WHODAS: World Health Organization Disability Assessment Schedule. Scores on the EQ-
5D-5L VAS and WHODAS 2.0 range from 0 to 100, with lower scores indicating poorer outcomes for the VAS, and better outcomes for
WHODAS 2.0.
Table 3. Serious adverse events.
Hypothermia Control
Event n¼ 49 n¼ 49
Symptomatic intracranial haemorrhage 4 2
Space-occupying oedema formation 4 1
Pneumonia 9 2
Other infection 4 1
Other serious adverse eventsa 11 10
aOther serious adverse events (n) included seizures (1); TIA (1); myo-
cardial infarction (1); impaired wound healing (2); haematuria (1); urinary
retention (1); carotid endarterectomy (1); B-cell lymphoma (1); ileus (1)
and pulmonary oedema (1) for hypothermia and TIA (1); cardiomyopathy
(1); atrial flutter (1); aneurysm formation (1); carotid endarterectomy (1);
bladder carcinoma (1); renal impairment (1); intoxication (1) and death of
unknown cause (2) for control. TIA: transient ischaemic attack.
6 European Stroke Journal 0(0)
In addition to evidence from animal studies that
cooling improves functional and pathological out-
comes in acute ischaemic stroke,23 the concept of our
trial was supported by randomised trials in adult
patients with cardiac arrest in the previous two deca-
des, demonstrating benefit of hypothermia.24 However,
in a more recent randomised trial in this patient popu-
lation, cooling to a target of 33C did not confer a
benefit as compared with maintaining body tempera-
ture at 36C.25 This suggests that in patients with car-
diac arrest outcomes may be improved by either
cooling to 36C, or by the prevention of sub-febrile
temperatures and fever. In patients with acute stroke,
elevated body temperatures have been associated with
an increased risk of a poor outcome23,26,27 and system-
atic review and meta-analysis of animal studies model-
ling ischaemic stroke have suggested that this relation
may in part be causal.28 Rather than active cooling, the
prevention of fever could therefore be a target to
improve outcomes after stroke. A randomised trial on
prevention of infections and fever in patients with mod-
erately severe to severe stroke is ongoing.29
Hypothermia is considered a powerful neuroprotec-
tive intervention in animal models of stroke, to the
extent that inadvertent cooling was held to confound
early laboratory studies. It might be argued that a fail-
ure of hypothermia to provide neuroprotection in
human stroke is further evidence that animal studies
do not model human pathophysiology with sufficient
fidelity to be a useful guide to developing new treat-
ments. However, differences in thermal mass mean that
the process of cooling a rodent brain can proceed much
more rapidly and with greater control than can be
achieved in the awake human brain in a busy ward,
and very few patients indeed achieved cooling to
target, so we do not believe that our findings have
any relevance to the question of the usefulness of
animal models. Future studies might explore the
effect of more direct approaches to cooling, for
instance through the instillation of cooled fluids direct-
ly to the cerebral circulation during endovascu-
lar procedures.
In conclusion, the limited feasibility of the interven-
tion under study at the current time and practical hur-
dles preventing sufficient recruitment into our trial
have prevented final conclusions on the benefit of
hypothermia in awake patients with acute ischaemic
stroke to be made. Improvement of the feasibility of
hypothermia in awake stroke patients and simplifica-
tion of the study design are required before this treat-
ment can be tested again in a randomised trial. For
now, the low feasibility that we encountered militates
against the premise of our study: with the current meth-
ods, hypothermia is unlikely to be a widely applicable
treatment for patients with acute ischaemic stroke.
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